[1] Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study[J]. Alimentary pharmacology & therapeutics. 2018,48(2):196-205.
[2] Kip KE, Swoger JM, Grandinetti LM, Barrie AM, 3rd, Greer JB, Regueiro MD. Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system[J]. Inflammatory bowel diseases. 2013,19(6):1164-72.
[3] Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis[J]. Gastroenterology. 2019,156(3):748-64.
[4] Perez-De-Lis M, Retamozo S, Flores-Chavez A, Kostov B, Perez-Alvarez R, Brito-Zeron P, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)[J]. Expert opinion on drug safety. 2017,16(11):1255-71.
[5] Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacology & therapeutics. 2008,117(2):244-79.
[6] Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab[J]. The Annals of pharmacotherapy. 2004,38(1):54-7.
[7] Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis[J]. Seminars in arthritis and rheumatism. 2010,40(3):233-40.
[8] Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature[J]. Alimentary pharmacology & therapeutics. 2011,34(11-12):1318-27.
[9] Puig L. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others[J]. Current problems in dermatology. 2018,53:49-63.
[10] Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G. Anti-Tumor Necrosis Factor-alpha-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients[J]. Digestive diseases and sciences. 2018,63(3):746-54.
[11] Guerra I, Algaba A, Perez-Calle JL, Chaparro M, Marin-Jimenez I, Garcia-Castellanos R, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases[J]. Journal of Crohn's & colitis. 2012,6(5):518-23.
[12] Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease[J]. Alimentary pharmacology & therapeutics. 2009,29(9):921-7.
[13] Guerra I, Perez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, et al. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study[J]. Inflammatory bowel diseases. 2016,22(4):894-901.
[14] Stoffel EM, H ; Riedl, E ;. <Pub.Med._Emmanuella_Guenova_2017-Analysis_of_anti-TNF-induced_skin_lesions.pdf>[J]. 2018.
[15] MD FAMHGT. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease – A systematic review and meta-analysis2019. DF-1.5 %âãÏÓ 2 0 obj <</Length1 75544/Filter/FlateDecode/Length 31557>>stream xœì¼w| Åÿ?>3Ûwoo÷.×’»\ÉåB9 @B FsTEz‹ ½K (͈Š ÅŠ]Qä€ p.
[16] Patel AS, Suarez LD, Rosh JR. Adalimumab in pediatric Crohn's disease[J]. Immunotherapy. 2016,8(2):127-33.
[17] Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes[J]. Systematic reviews. 2017,6(1):243.
[18] Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy[J]. Inflammatory bowel diseases. 2018.
[19] Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy[J]. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010,8(12):1048-55.
[20] Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study[J]. Annals of internal medicine. 2016,164(1):10-22.
[21] Freling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience[J]. The American journal of gastroenterology. 2015,110(8):1186-96.
[22] Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease[J]. Journal of pediatric gastroenterology and nutrition. 2011,52(2):230-2.
[23] T M. <Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease_ a 2-year prospective study..pdf>[J]. Inflammatory bowel diseases. 2014,20:1309-15.
[24] LA G, A G, RK C, G J, LJ G. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease[J]. Digestive diseases and sciences. 2015,60(11):3424-30.
[25] Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series[J]. Journal of Crohn's & colitis. 2014,8(6):480-8.
[26] Sondermann W, Herz S, Sody E, Korber A. Dermatological complications of therapy with biologics in inflammatory autoimmune diseases[J]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2019,17(10):1029-37.
[27] Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents[J]. Pediatric dermatology. 2017,34(3):253-60.
[28] S KJ, AM T, M H, F S, D M. Anti-TNFα antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study[J]. QJM : monthly journal of the Association of Physicians. 2017,110(6):379-82.
[29] Weizman AV, Sharma R, Afzal NM, Xu W, Walsh S, Stempak JM, et al. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease[J]. Digestive diseases and sciences. 2018,63(9):2430-8.
[30] Peer FC, Miller A, Pavli P, Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients[J]. Internal medicine journal. 2017,47(12):1445-8.
[31] Toussirot E, Aubin F. Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview[J]. RMD open. 2016,2(2):e000239.
[32] Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study[J]. Alimentary pharmacology & therapeutics. 2015,42(7):880-8.
[33] Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases[J]. Journal of Crohn's & colitis. 2013,7(7):517-24.
[34] Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases[J]. The Journal of dermatological treatment. 2009,20(2):100-8.
[35] Almutairi D, Sheasgreen C, Weizman A, Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease[J]. Journal of cutaneous medicine and surgery. 2018,22(5):507-10.
[36] Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L. Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature[J]. Acta dermatovenerologica Croatica : ADC. 2016,24(3):169-74.
[37] Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management[J]. Journal of psoriasis and psoriatic arthritis. 2019,4(2):70-80.
[38] Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity[J]. Archives of dermatology. 2007,143(2):239-42.
[39] Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, et al. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons[J]. Clinical therapeutics. 2017,39(4):849-62 e6.
[40] Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis[J]. Nature communications. 2018,9(1):25.
[41] M P, A S, N Y, S V, F S. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels[J]. Scandinavian journal of gastroenterology. 2016,51(12):1482-8.
[42] Vedak P, Kroshinsky D, St John J, Xavier RJ, Yajnik V, Ananthakrishnan AN. Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis[J]. Alimentary pharmacology & therapeutics. 2016,43(6):697-704.
[43] Darrigade AS, Milpied B, Truchetet ME, Schaeverbeke T, Laharie D, Zerbib F, et al. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors[J]. Acta dermato-venereologica. 2017,97(6):731-4.
[44] Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register[J]. Annals of the rheumatic diseases. 2009,68(2):209-15.
[45] Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease[J]. Alimentary pharmacology & therapeutics. 2013,38(9):1002-24.
[46] Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, et al. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network[J]. Clinics and research in hepatology and gastroenterology. 2019.
[47] Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment[J]. Gut. 2014,63(4):567-77.
[48] Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, et al. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease[J]. Journal of pediatric gastroenterology and nutrition. 2019,69(2):189-93.
[49] Hellstrom AE, Farkkila M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease[J]. Scandinavian journal of gastroenterology. 2016,51(5):563-71.
[50] Soh JS, Yun WJ, Kim KJ, Won CH, Park SH, Yang DH, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions[J]. Inflammatory bowel diseases. 2015,21(4):832-9.
[51] Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases[J]. Expert review of clinical immunology. 2019:1-12.
[52] Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D. Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics[J]. Therapeutic drug monitoring. 2017,39(4):370-8.
[53] Gole B, Potocnik U. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis[J]. Cells. 2019,8(6).
[54] Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review[J]. International journal of dermatology. 2018,57(12):1521-32.
[55] Protic M SA, Yawalkar N, et al. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels[J]. Scandinavian journal of gastroenterology. 2016, 51:1482–8.
[56] Coutzac C CJ, Poullenot F, et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study[J]. Journal of Crohn’s & colitis. 2015,9: 982-7.
[57] Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study[J]. Inflammatory bowel diseases. 2017,23(7):1174-81.